Critical analysis of US Patent 10,544,125: crystalline XRPD forms and combination-treatment claims

US 10,544,125 centers on (i) defined crystalline forms of a cyclopropanamine scaffold with a complex indole-quinoline ether substitution pattern, with XRPD peak lists and intensity constraints, and (ii) broad oncology treatment method claims that pair the salt/crystalline form with a second therapeutic agent (chemotherapy, immunotherapy, anti-VEGF) and optionally a third agent. The claims are heavily claim-type layered: solid-state definition first, then formulation state (salt), then combination use. That structure can strengthen patent defensibility against form/design-around for the specific polymorph/salt, while simultaneously creating breadth vulnerabilities for method claims (because the “second therapeutic agent” is recited at a generic class or enumerated-drug level).

What exactly is being claimed: XRPD-defined crystalline forms and specific salts?

Claim 1: crystalline form of the full parent cyclopropanamine base with a 27-peak XRPD set

Claim 1 defines a crystalline form of:

1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quino-lin-7-yloxy)methyl)cyclopropanamine

It requires the crystalline form exhibits XRPD characteristic peaks at 2θ angles (27 peaks listed):

7.640, 8.642, 9.361, 10.091, 13.740, 14.479, 15.186, 15.766, 17.206, 18.569, 19.271, 20.041, 22.211, 22.814, 23.398, 24.455, 25.524, 26.703, 27.337, 28.061, 28.801, 29.845, 31.331, 31.621, 32.840, 33.714, 38.348.

Claim 2 and 3: intensity and d-spacing constraints tied to the same crystalline form

Claim 2: peaks have intensity > about 10%.
Claim 3: d-values are specified (27 d-values), e.g. 11.56173, 10.22328, 9.43969, 8.75881, 6.43957, …, 2.34534.

These two features convert the XRPD definition from “presence” into “quantitative banding,” which can reduce freedom for competitors who attempt to use close-but-not-identical polymorphs.

Claim 4: intensity values recited for the 27 peaks

Claim 4 lists explicit intensity (%) values for the same numbered peaks. Key intensities include:

Peak #	Intensity (%)
4	100.0
5	26.4
6	54.7
12	49.5
13	58.4
16	76.6
17	34.6
19	18.4
20	18.5
27	9.6

This is a more enforceable solid-state posture than a pure peak-angle list because it ties the claim to a specific relative diffractogram signature rather than merely the approximate existence of peaks.

Claim 5: bishydrochloride salt

Claim 5 states the compound (from Claim 1) is a bishydrochloride salt.

This matters because polymorph-to-salt interactions often shift XRPD patterns. The claim set therefore tries to “lock” both the lattice form and the salt identity for at least one commercial-ready preparation path.

How broad are the treatment method claims, and where are the real leverage points?

Claims 6-16: combination therapy methods using salt forms plus a second agent, with a large disease set

Claim 6 claims a method of treating a neoplastic disease by:

administering a salt of the cyclopropanamine,
administering a second therapeutic agent,
where the neoplastic disease includes:
- Solid tumors: lung, renal, colorectal, gastric, melanoma, head/neck, thyroid, pancreatic, liver, prostate, bladder, brain, sarcoma, breast, ovarian, cervical, endometrial.
- Blood cancers: ALL, CLL, AML, CML, Multiple Myeloma.
and the salt is selected from:
- bishydrochloride acid salt
- bishydrochloride hydrate acid salt
- bismaleic acid salt
- succinic acid salt

Claim 7-11 tier:

Claim 7: second therapeutic agent is a chemotherapeutic agent.
Claim 8: second therapeutic agent is a platinum-based agent and a taxane-based agent.
Claim 9: second therapeutic agent is selected from paclitaxel, cisplatin, carboplatin.
Claim 10: further administering a third therapeutic agent.
Claim 11: if second is paclitaxel, third is cisplatin or carboplatin.

Claims 12-15 add immunotherapy:

Claim 12: third therapeutic agent is an immunotherapy agent.
Claim 13: immunotherapy selected from nivolumab, pembrolizumab, ipilimumab, blinatumomab, elotuzumab, daratumumab, and talimogene laherparepvec.

Claims 14-15 also recite immunotherapy as second agent directly:

Claim 14: second therapeutic agent is an immunotherapy agent.
Claim 15: same enumerated immunotherapies as Claim 13.

Claims 16 recites anti-VEGF:

Claim 16: second therapeutic agent is an anti-VEGF antibody or a VEGF trap.

Critical breadth assessment

The method claims are broad in three dimensions:

Indication breadth
- The solid tumor list spans most major organs (lung, GI, GU, breast, gynecologic, brain, thyroid, pancreas).
- The blood cancer list spans key hematologic malignancies (ALL/CLL/AML/CML and Multiple Myeloma).
Combination breadth
- The second agent is defined by very common oncology therapy categories (chemotherapy, immunotherapy, anti-VEGF).
- Specific second-agent instances are recited at least for some tiers (paclitaxel/cisplatin/carboplatin; enumerated checkpoint/antibody/cell therapy items).
Salt breadth
- Claim 6 locks the use to salts including multiple counterions and hydrate status for bishydrochloride.
- The XRPD-defined crystalline form is not repeated in Claim 6’s text, but the claimed “salt of the compound” ties the method to the salt identity used with the core structure.

Leverage point: the method claims are anchored to the use of the claimed salt(s), not to the second agents themselves. That allows enforceability even if the combination of, say, paclitaxel with checkpoint therapy is widely known, as long as the accused regimen uses the claimed salt/crystalline form.

Vulnerability point: the method claims do not recite:

dose ranges,
scheduling/sequence parameters,
response biomarkers,
line of therapy (first line vs later),
tumor-specific performance.

That can matter for novelty/inventive step attacks, because broad oncology combination method claims often face prior-art combinations and general “treat cancer by giving drug A plus drug B” teaching.

Does the patent also claim a second crystalline form?

Yes. Claims 17-20 add a second crystalline form with a much shorter XRPD peak list.

Claim 17: crystalline form of the base with 5 XRPD peaks

Claim 17 defines a crystalline form of:

1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quino-lin-7-yloxy)methyl)cyclopropanamine

with XRPD peaks at 2θ angles:

10.091
14.479
20.041
22.211
24.455

Claim 18: intensity > about 10% for those peaks

peaks intensity greater than about 10%.

Claim 19-20: method claims using the compound of Claim 17

Claim 19 recites a method of treating neoplastic disease by administering:
- the compound of Claim 17
- plus a second therapeutic agent
- with the same large solid tumor and blood cancer sets as Claim 6.
Claim 20 adds a third therapeutic agent (no specific class recited in the excerpt).

Critical comparison: Claim 1 vs Claim 17 crystalline scope

Claim 1 crystalline form is defined by 27 peaks plus intensities and d-values, which is a tight solid-state fingerprint.
Claim 17 crystalline form is defined by only 5 peaks (and intensity threshold), which is a weaker structural sieve.
- In enforcement, a shorter peak list can increase the risk that unrelated polymorphs or even amorphous/mixture-containing materials could share those 5 peaks depending on measurement conditions.
- In validity challenges, shorter definitions can also be easier to match by prior art if earlier datasets show those peak positions.

Claim-by-claim enforceability and design-around map

Strongest claim components (most likely to create enforceable “hooks”)

Claim 4 (27 peak intensities)
- The presence of a numbered intensity list with a 100% maximum at peak #4 and multiple mid-to-high peaks (for example 49.5%, 58.4%, 76.6%) creates a higher bar for literal infringement and can also support infringement under typical XRPD interpretation rules if the reference spectrum is close.
Claim 3 (explicit d-spacing list)
- d-values act like a secondary coordinate system that can catch “peak-shift” cheats where 2θ matches but spacing differs due to instrument calibration or sample displacement.
Claim 5 and Claim 6 salt list
- The specific salts and inclusion of bishydrochloride hydrate are narrower than a generic “any pharmaceutically acceptable salt.”

Most vulnerable components (highest prior-art and indefiniteness risk)

Claim 17/18 crystalline form defined by only 5 peaks
- The limitation is simpler and can be matched or approximated more easily.
Claim 6’s method breadth
- Huge indication list plus broad combination categories without regimen specifics invites obviousness/non-obviousness attacks based on generic combination oncology practice.
Claims 14-15 immunotherapy enumeration
- While enumerated drugs can improve clarity, immunotherapy combinations are often already taught across multiple cancer types, making it harder to argue for a distinct inventive concept unless the patent’s core data ties the specific salt to an unexpected effect.

Where would prior art most likely attack this landscape?

Solid-state (polymorph/salt) prior art attack channels

Competitors and challengers typically try to show one of the following:

the same crystalline form already existed (or was implicitly disclosed) with the same XRPD signature,
the cited XRPD peaks match known polymorphs of structurally close analogs,
the salt identity (bishydrochloride hydrate, bismaleate, succinate) is known for the same base drug and shares the same XRPD peaks.

The “quantitative tightening” in Claim 3 and Claim 4 is intended to reduce this. The second crystalline form in Claim 17 is easier to overlap with prior datasets due to its minimal peak set.

Method claims attack channels

Prior art combinations: general teachings that “drug A plus chemotherapy/immunotherapy/anti-VEGF treats cancer.”
Broad oncology treatment lists: patents and papers often include long organ-by-organ and hematology lists.
Lack of distinguishing features: no dosing/schedule/sequence or biomarker.

Because Claim 6 is anchored to the claimed salt, prior art that teaches combination therapy using the same compound can be the main threat; prior art using different salts or different crystalline forms can also threaten validity depending on how broadly “salt of the compound” is construed versus crystalline form constraints.

Business implications: what the claim architecture signals for freedom-to-operate (FTO) and R&D

If you are developing a product using this scaffold

Solid-state control is central
- The patent landscape implies that competing on formulation without matching the XRPD fingerprint (Claim 1/4 for the 27-peak form; Claim 17 for the 5-peak form) is a viable strategy if the competitor can demonstrate a different crystalline form and different salt.
Salt selection is a legal risk lever
- Using different counterions than the four listed in Claim 6 may help move outside those method claims, but it does not avoid infringement if a different claim path still covers the formulation you use.
Combination regimen specificity matters
- The broadness of the method claims means that changing the second therapeutic agent class may or may not avoid infringement. Claim 6 covers broad categories and multiple agent examples across tiers.

If you are assessing patent value

Value is strongest where infringement is tied to a measurable, instrument-based solid-state fingerprint (Claim 1/3/4).
Value is weaker where the claim relies on broad combination oncology statements without clinical or regimen constraints (Claim 6, plus immunotherapy/chemo tiers).

Claim set summary table (scope and constraints)

Claim	Target	Key limitations
1	Crystalline form of base	27 XRPD peaks at listed 2θ angles
2	Claim 1	All characteristic peaks intensity > about 10%
3	Claim 1	d-values specified for 27 peaks
4	Claim 1	intensity (%) specified for 27 peaks (includes 100% at peak #4)
5	Salt form	bishydrochloride salt
6	Method	administer claimed salt (bishydrochloride, bishydrochloride hydrate, bismaleate, succinate) + second agent; disease list is broad across solid tumors and blood cancers
7-9	Method tier	second agent is chemo; specified classes and drugs include paclitaxel/cisplatin/carboplatin
10-11	Method tier	add third agent; if second is paclitaxel, third is cisplatin/carboplatin
12-15	Method tier	third agent is immunotherapy; second agent can also be immunotherapy (includes nivolumab, pembrolizumab, ipilimumab, blinatumomab, elotuzumab, daratumumab, T-VEC)
16	Method tier	second agent is anti-VEGF antibody or VEGF trap
17	Crystalline form #2	5 XRPD peaks at listed 2θ angles
18	Claim 17	intensity > about 10% for those 5 peaks
19-20	Method using crystalline form #2	administer Claim 17 compound + second agent; disease list broad; third agent added in Claim 20

Key Takeaways

US 10,544,125 is built around XRPD-defined crystalline forms and then uses those specific solid states as anchors for broad oncology combination methods.
Claim 1-4 are the strongest enforceability zone because the crystalline form is defined with a detailed 27-peak XRPD signature plus d-values and explicit intensities.
Claim 17-18 are comparatively weaker from an infringement and validity standpoint because they rely on only five XRPD peaks.
The method claims are broad across cancer indications and combination partner classes (chemo, immunotherapy, anti-VEGF). The enforceable hook is the use of the claimed salt/crystalline form rather than any regimen-specific feature.

FAQs

1) Does the patent cover multiple crystalline polymorphs of the same base compound?

Yes. It claims at least two crystalline forms: Claim 1 (27-peak XRPD set with d-values and intensities) and Claim 17 (5-peak XRPD set).

2) Are the salt forms limited to a single counterion?

No. Claim 6 lists multiple salt options for the method: bishydrochloride, bishydrochloride hydrate, bismaleate, and succinate.

3) What combination partners are explicitly covered in the method claims?

At minimum, the claims name chemotherapy agents (including paclitaxel, cisplatin, carboplatin), enumerated immunotherapies (nivolumab, pembrolizumab, ipilimumab, blinatumomab, elotuzumab, daratumumab, T-VEC), and anti-VEGF antibody/VEGF trap categories.

4) Which claims are most likely to be hardest to design around?

Claims with the most detailed solid-state characterization, especially Claim 4’s explicit 27-peak intensity list and Claim 3’s d-spacing list.

5) Does the claim set require specific dosing or treatment scheduling?

In the provided claim text, no dosing, timing, or sequencing parameters are recited. The method claims are framed by agent categories and optional third-agent addition.

References

[1] United States Patent US 10,544,125 (claim text provided by user).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	March 25, 2011	10,544,125	2038-09-07
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	10,544,125	2038-09-07
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	10,544,125	2038-09-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016179123	⤷ Start Trial
United States of America	9751859	⤷ Start Trial
United States of America	2019002435	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 10,544,125

Summary for Patent: 10,544,125